GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Octreotide

Company
St. James's Hospital, Ireland
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
30 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

30 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Octreotide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT02019706

    Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome

    Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 80 participants Est. completion 2030-12-31 1 site
    Other conditions: ACTH, Cushing's Syndrome
    View official trial listing →
  • Recruiting NCT NCT03158090

    The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research

    Ginkgo Leaf Center for Rare Disorders 1965 participants Est. completion 2051-01-30 1 site
    Other conditions: Acromegaly
    View official trial listing →
  • Recruiting NCT NCT04917484

    Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients

    Not yet reported Tine Gregersen, MD 100 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Neuroendocrine Neoplasm
    View official trial listing →
  • Recruiting NCT NCT04997317

    Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide

    Not yet reported, Not yet reported University Hospital, Basel, Switzerland 18 participants Est. completion 2026-12-31 1 site
    Other conditions: Meningioma
    View official trial listing →
  • Recruiting NCT NCT05387603

    Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.

    Not yet reported Lund University Hospital 300 participants Est. completion 2026-10-01 4 sites
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Recruiting NCT NCT05477576

    Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

    Not yet reported RayzeBio, Inc. 338 participants Est. completion 2030-12 54 sites
    Other conditions: GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
    View official trial listing →
  • Recruiting NCT NCT05701241

    Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients

    Not yet reported University Hospital, Antwerp 270 participants Est. completion 2034-04 19 sites
    Other conditions: Gastroenteropancreatic Neuroendocrine Tumor
    View official trial listing →
  • Recruiting NCT NCT05749289

    Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression

    Not yet reported, Not yet reported Cancer Institute and Hospital, Chinese Academy of Medical Sciences 400 participants Est. completion 2029-12-20 1 site Stand-alone
    Other conditions: SSTR Positive Tumors
    View official trial listing →
  • Recruiting NCT NCT05833217

    Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

    Not yet reported Stanford University 55 participants Est. completion 2025-12-31 2 sites Stand-alone
    Other conditions: Long COVID, Insulin Resistance, Insulin Sensitivity
    View official trial listing →
  • Recruiting NCT NCT05884255

    An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

    Not yet reported Jiangsu HengRui Medicine Co., Ltd. 220 participants Est. completion 2030-10 2 sites Stand-alone
    Other conditions: Advanced Gastroenteropancreatic Neuroendocrine Tumor
    View official trial listing →
  • Recruiting NCT NCT05918302

    Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

    Not yet reported Grupo Espanol de Tumores Neuroendocrinos 170 participants Est. completion 2029-10 27 sites
    Other conditions: Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms
    View official trial listing →
  • Recruiting NCT NCT06045260

    "Receptor Radionuclide Therapy With 177Lu-DOTATOC

    Not yet reported Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 100 participants Est. completion 2027-01 2 sites
    Other conditions: Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma
    View official trial listing →
  • Recruiting NCT NCT06326190

    177Lu-DOTATATE for Recurrent Meningioma

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC 136 participants Est. completion 2028-12-22 19 sites
    Other conditions: Recurrent Meningioma
    View official trial listing →
  • Recruiting NCT NCT06345079

    Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

    Not yet reported Australasian Gastro-Intestinal Trials Group 78 participants Est. completion 2028-06 17 sites Stand-alone
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Recruiting NCT NCT06441331

    Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

    Not yet reported ITM Solucin GmbH 20 participants Est. completion 2034-04 6 sites
    Obstructive sleep apnea Other conditions: Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor, CNS Tumors, Peripheral Primitive Neuroectodermal Tumor, GIST
    View official trial listing →
  • Recruiting NCT NCT06505395

    A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

    Not yet reported CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 90 participants Est. completion 2028-08-01 1 site
    Other conditions: Gastrointestinal Neuroendocrine Pancreatic Tumor
    View official trial listing →
  • Recruiting NCT NCT06592261

    Graded Insulin Suppression Test P&F

    Not yet reported Columbia University 15 participants Est. completion 2026-09 1 site Stand-alone
    Other conditions: Insulin Resistance, Hyperinsulinemia, Obesity, Healthy
    View official trial listing →
  • Recruiting NCT NCT06784752

    Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

    Not yet reported Novartis Pharmaceuticals 240 participants Est. completion 2034-01-23 65 sites Stand-alone
    Other conditions: Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
    View official trial listing →
  • Recruiting NCT NCT06878664

    Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors

    Not yet reported Grupo Espanol de Tumores Neuroendocrinos 166 participants Est. completion 2029-01 21 sites Stand-alone
    Other conditions: Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)
    View official trial listing →
  • Recruiting NCT NCT06881628

    Tranxemic Acid and Vitamin K Injection to Control Upper Gastrointestinal Bleeding in Cirrhotic Patients

    Not yet reported Tanta University 194 participants Est. completion 2025-12-30 1 site Stand-alone
    Other conditions: Upper Gastrointestinal Bleeding (UGIB), Variceal Bleeding, Cirrhosis
    View official trial listing →
  • Recruiting NCT NCT06930625

    A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

    Not yet reported Debiopharm International SA 119 participants Est. completion 2029-03 73 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Recruiting NCT NCT07057622

    A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs

    Not yet reported HTA Co., Ltd. 184 participants Est. completion 2027-02-24 1 site
    Other conditions: NETS Ga68 Lu177
    View official trial listing →
  • Recruiting NCT NCT07087054

    Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

    Not yet reported Crinetics Pharmaceuticals Inc. 141 participants Est. completion 2030-01 67 sites
    Other conditions: Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor
    View official trial listing →
  • Recruiting NCT NCT07104487

    [18F]AlF-NOTA-octreotide PET/MRI in Carotid Artery Disease

    Not yet reported Universitaire Ziekenhuizen KU Leuven 24 participants Est. completion 2029-09 1 site Stand-alone
    Cardiovascular disease Other conditions: Carotid Artery Plaque, Carotid Arteriosclerosis
    View official trial listing →
  • Recruiting NCT NCT07165886

    Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

    Not yet reported, Not yet reported CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 298 participants Est. completion 2028-08-29 1 site Stand-alone
    Other conditions: Gastroenteropancreatic Neuroendocrine Tumors
    View official trial listing →
  • Recruiting NCT NCT07195500

    Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma

    Nanjing First Hospital, Nanjing Medical University 30 participants Est. completion 2028-06-30 1 site
    Other conditions: Neuroblastoma, Pheochromocytoma, Paraganglioma
    View official trial listing →
  • Recruiting NCT NCT07255248

    Hoffa's Fat Pad Impingement (HFPI)

    Not yet reported Boston Children's Hospital 62 participants Est. completion 2028-01-02 1 site
    Other conditions: Hoffa's Fat Pad Impingement
    View official trial listing →
  • Recruiting NCT NCT07262957

    Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)

    Not yet reported Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 400 participants Est. completion 2027-12-01 1 site Stand-alone
    Other conditions: Pancreas Head Cancer, Pancreas Adenocarcinoma, IPMN, Pancreatic, Cholangio Carcinoma, Ampulla of Vater Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Duodenal Carcinoma, Mucinous Cystic Neoplasm, Neuro Endocrine Tumours, Pancreatitis
    View official trial listing →
  • Recruiting NCT NCT07403604

    Effect of Insulin Lowering on Lipogenesis

    Not yet reported Columbia University 25 participants Est. completion 2029-09-30 1 site Stand-alone
    Other conditions: Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
    View official trial listing →
  • Recruiting NCT NCT07583563

    An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly

    Camurus AB 200 participants Est. completion 2029-06 6 sites
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00001228

    Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer

    Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 50 participants Est. completion 2007-09-06 1 site
    Other conditions: Islet Cell Adenoma, Zollinger Ellison Syndrome
    View official trial listing →
  • Completed NCT NCT00001849

    New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

    Not yet reported Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 95 participants Est. completion 2019-04-26 1 site
    Other conditions: Cushing Syndrome, Endocrine Disease
    View official trial listing →
  • Completed NCT NCT00001860

    Sandostatin LAR Depot vs. Surgery for Treating Acromegaly

    Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 5 participants Est. completion 2002-07 1 site
    Other conditions: Acromegaly, Pituitary Neoplasm
    View official trial listing →
  • Completed NCT NCT00002252

    A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea

    Not yet reported Sandoz 23 sites
    Other conditions: Diarrhea, HIV Infections
    View official trial listing →
  • Completed NCT NCT00002253

    A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.

    Not yet reported Sandoz 22 sites
    Other conditions: Diarrhea, HIV Infections
    View official trial listing →
  • Completed NCT NCT00002779

    Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

    Not yet reported Alliance for Clinical Trials in Oncology 34 participants Est. completion 2015-06 20 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00002864

    Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

    Not yet reported NCIC Clinical Trials Group 667 participants Est. completion 2010-04-23 40 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT00002947

    Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

    Not yet reported Yale University 35 participants Est. completion 2004-08 1 site
    Other conditions: Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer, Intraocular Melanoma, Islet Cell Tumor, Kidney Cancer, Lung Cancer, Melanoma (Skin), Neoplastic Syndrome, Neuroendocrine Carcinoma of the Skin, Pheochromocytoma
    View official trial listing →
  • Completed NCT NCT00002967

    Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

    Not yet reported NSABP Foundation Inc Est. completion 2006-03 108 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00003057

    Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer

    Not yet reported Eastern Cooperative Oncology Group 500 participants 33 sites
    Other conditions: Colorectal Cancer, Diarrhea
    View official trial listing →
  • Completed NCT NCT00003283

    Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma

    Not yet reported Eastern Cooperative Oncology Group 38 participants 25 sites
    Other conditions: Thymoma and Thymic Carcinoma
    View official trial listing →
  • Completed NCT NCT00004327

    Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia

    Not yet reported National Center for Research Resources (NCRR) 8 participants
    Other conditions: Hereditary Hemorrhagic Telangiectasia, Ectasia
    View official trial listing →
  • Completed NCT NCT00004895

    Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

    Not yet reported Northwestern University Est. completion 2002-10 1 site
    Other conditions: Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor, Nausea and Vomiting, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cavity Cancer, Small Intestine Cancer
    View official trial listing →
  • Completed NCT NCT00005906

    Treatment With Octreotide in Patients With Lymphangioleiomyomatosis

    Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 4 participants 1 site Stand-alone
    Other conditions: Lymphangioleiomyomatosis, Lymphangiomyomas, Pleural Effusions, Ascites
    View official trial listing →
  • Terminated NCT NCT00006269

    Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

    Not yet reported Novartis 89 participants 2 sites
    Other conditions: Colorectal Cancer, Diarrhea
    View official trial listing →
  • Completed NCT NCT00006368

    Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

    Not yet reported Novartis Pharmaceuticals 60 participants Est. completion 2003-11 1 site
    Other conditions: Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
    View official trial listing →
  • Completed NCT NCT00006370

    Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer

    Not yet reported Novartis Pharmaceuticals 275 participants Est. completion 2004-06 1 site
    Other conditions: Breast Cancer, Lung Cancer
    View official trial listing →
  • Completed NCT NCT00008073

    Octreotide and Doxorubicin in Treating Patients With Advanced Cancer

    Not yet reported University of Pittsburgh Est. completion 2002-05 1 site
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00033605

    Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis

    Not yet reported Alliance for Clinical Trials in Oncology 130 participants Est. completion 2006-07 Stand-alone
    Other conditions: Cervical Cancer, Colorectal Cancer, Diarrhea, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific, Vaginal Cancer, Vulvar Cancer
    View official trial listing →
  • Completed NCT NCT00049023

    Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

    Not yet reported O'Dorisio, M S 27 participants Est. completion 2011-08 1 site Stand-alone
    Other conditions: Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma, Pheochromocytoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00050635

    STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea

    Not yet reported Novartis Pharmaceuticals 150 participants Est. completion 2003-07 34 sites
    Other conditions: Neoplasms, Diarrhea
    View official trial listing →
  • Completed NCT NCT00068029

    Pegvisomant And Sandostatin LAR Combination Study

    Not yet reported Pfizer 75 participants Est. completion 2006-05 33 sites
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00068042

    A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly

    Not yet reported Pfizer 100 participants Est. completion 2006-05 55 sites
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00075868

    Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

    Not yet reported Radiation Therapy Oncology Group 233 participants 112 sites Stand-alone
    Other conditions: Anal Cancer, Colorectal Cancer, Drug/Agent Toxicity by Tissue/Organ, Radiation Enteritis
    View official trial listing →
  • Completed NCT NCT00076362

    Pediatric Hypothalamic Obesity

    Not yet reported Novartis Pharmaceuticals 60 participants 15 sites
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT00088582

    Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients

    Not yet reported Novartis Pharmaceuticals 62 participants 5 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00088595

    Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

    Not yet reported Novartis Pharmaceuticals 45 participants Est. completion 2008-07 4 sites
    Other conditions: Carcinoid Tumors
    View official trial listing →
  • Terminated NCT NCT00092287

    Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

    Not yet reported Ipsen 4 participants Est. completion 2004-10 1 site
    Other conditions: Malignant Carcinoid Syndrome
    View official trial listing →
  • Completed NCT NCT00094146

    Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity

    Not yet reported Novartis 160 participants Est. completion 2002-12 3 sites
    Other conditions: Primary Insulin Hypersecretion, Obesity
    View official trial listing →
  • Completed NCT NCT00108355

    Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis

    Not yet reported US Department of Veterans Affairs 29 participants Est. completion 2012-08 1 site Stand-alone
    Other conditions: Ascites, Cirrhosis
    View official trial listing →
  • Completed NCT NCT00113360

    RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

    Not yet reported M.D. Anderson Cancer Center 67 participants Est. completion 2009-07 1 site Stand-alone
    Other conditions: Neuroendocrine Carcinoma, Islet Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT00128232

    Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients

    Not yet reported Novartis 100 participants
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00130845

    Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

    Not yet reported Novartis 312 participants Est. completion 2005-12 1 site Stand-alone
    Other conditions: Diabetic Retinopathy
    View official trial listing →
  • Completed NCT NCT00131144

    Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

    Not yet reported Novartis 583 participants Est. completion 2005-12 1 site Stand-alone
    Other conditions: Diabetic Retinopathy
    View official trial listing →
  • Completed NCT NCT00145405

    Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction

    Not yet reported Odense University Hospital 12 participants Est. completion 2004-12 1 site
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00166725

    Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients

    Not yet reported Novartis 40 participants 1 site
    Other conditions: Prostate Cancer
    View official trial listing →
  • Terminated NCT NCT00170742

    Study to Assess the Efficacy and Safety of Monthly Octreotide Intramuscular Injections in Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study is Not Being Conducted in the United States.

    Not yet reported Novartis 17 participants 1 site
    Other conditions: Proliferative Diabetic Retinopathy
    View official trial listing →
  • Completed NCT NCT00171613

    A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients

    Not yet reported Novartis 32 participants
    Other conditions: Hypothalamic Obesity
    View official trial listing →
  • Completed NCT NCT00171730

    An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly

    Not yet reported Novartis Pharmaceuticals 30 participants Est. completion 2013-12-06 10 sites
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00171873

    Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut

    Not yet reported Carmen Schade-Brittinger 85 participants Est. completion 2013-12 10 sites Stand-alone
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Completed NCT NCT00171886

    Octreotide Efficacy and Safety in First-line Acromegalic Patients

    Not yet reported Novartis Pharmaceuticals 20 participants Est. completion 2006-05 8 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Terminated NCT NCT00175305

    Prader-Willi Syndrome and Appetite

    Not yet reported University of British Columbia 10 participants Est. completion 2007-10 1 site
    Other conditions: Hyperphagia, Prader-Willi Syndrome
    View official trial listing →
  • Completed NCT NCT00182754

    Octreotide in Treating Patients With Cancer-Related Malignant Ascites

    Not yet reported Alliance for Clinical Trials in Oncology 33 participants Est. completion 2013-03 122 sites Stand-alone
    Other conditions: Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00216398

    Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

    Not yet reported Ipsen 8 participants Est. completion 2006-06-22 1 site
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00222092

    Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers

    University of Ioannina 300 participants Est. completion 2006-09 1 site
    Other conditions: Post-ERCP Acute Pancreatitis
    View official trial listing →
  • Completed NCT NCT00223691

    Treatment of Orthostatic Hypotension in Autonomic Failure

    Not yet reported Vanderbilt University 389 participants Est. completion 2017-01 1 site Stand-alone
    Other conditions: Autonomic Failure, Orthostatic Hypotension
    View official trial listing →
  • Completed NCT NCT00225979

    Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly

    Not yet reported Novartis Pharmaceuticals 100 participants Est. completion 2005-03 Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00226967

    Stress, Diurnal Cortisol, and Breast Cancer Survival

    Stanford University 115 participants Est. completion 2005-12 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT00227773

    Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

    Not yet reported Eastern Cooperative Oncology Group
    Other conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT00234520

    A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide

    Ipsen 225 participants Est. completion 2005-02-18 33 sites
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00240045

    The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction

    Not yet reported, Not yet reported University of Alberta 9 participants Est. completion 2007-07 1 site Stand-alone
    Other conditions: Type 2 Hepatorenal Syndrome, Refractory Ascites
    View official trial listing →
  • Completed NCT NCT00241020

    Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma

    Not yet reported Novartis Pharmaceuticals 270 participants Est. completion 2005-10 Stand-alone
    Other conditions: Advanced Hepatocellular Carcinoma
    View official trial listing →
  • Terminated NCT NCT00242541

    Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas

    Not yet reported Novartis Pharmaceuticals 50 participants 1 site Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Terminated NCT NCT00248131

    Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

    Not yet reported Novartis Pharmaceuticals 260 participants Est. completion 2006-07
    Other conditions: Diabetic Retinopathy
    View official trial listing →
  • Terminated NCT NCT00248157

    Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

    Not yet reported Novartis Pharmaceuticals 105 participants Est. completion 2006-05
    Other conditions: Diabetic Retinopathy
    View official trial listing →
  • Completed NCT NCT00250796

    Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma

    Not yet reported University of New Mexico 12 participants Est. completion 2006-03 2 sites Stand-alone
    Other conditions: Liver, Cancer
    View official trial listing →
  • Completed NCT NCT00257426

    Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer

    Not yet reported UNC Lineberger Comprehensive Cancer Center 31 participants Est. completion 2009-09 1 site
    Other conditions: Liver Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT00262470

    Treatment of Orthostatic Intolerance

    Not yet reported, Not yet reported Satish R. Raj 150 participants Est. completion 2029-12 1 site Stand-alone
    Other conditions: Tachycardia, Chronic Orthostatic Intolerance
    View official trial listing →
  • Status unknown NCT NCT00274170

    Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache

    Not yet reported, Not yet reported C.R.Darnall Army Medical Center 56 participants Est. completion 2007-02 1 site
    Other conditions: Migraine Headache
    View official trial listing →
  • Completed NCT NCT00309283

    Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study

    Not yet reported Mario Negri Institute for Pharmacological Research 78 participants Est. completion 2012-01 5 sites
    Other conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    View official trial listing →
  • Completed NCT NCT00332696

    Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

    Not yet reported Novartis Pharmaceuticals 64 participants Est. completion 2008-09 1 site Stand-alone
    Other conditions: Peritoneal Neoplasms, Intestinal Obstruction, Carcinomatosis
    View official trial listing →
  • Completed NCT NCT00332969

    Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma

    Not yet reported Novartis Pharmaceuticals 25 participants 1 site Stand-alone
    Other conditions: Thymoma
    View official trial listing →
  • Completed NCT NCT00363051

    Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

    Not yet reported Novartis Pharmaceuticals 160 participants Est. completion 2012-04 54 sites Stand-alone
    Other conditions: Islet Cell Carcinoma, Neuroendocrine Carcinoma, Neuroendocrine Tumor, Pancreatic Neoplasms
    View official trial listing →
  • Completed NCT NCT00372697

    Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly

    Not yet reported Novartis Pharmaceuticals 28 participants Est. completion 2007-10 1 site Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00376064

    Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

    Not yet reported Novartis Pharmaceuticals 20 participants 16 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00386984

    Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma

    Not yet reported University Hospital Freiburg 108 participants Est. completion 2003-02 1 site
    Other conditions: Carcinoma, Hepatocellular
    View official trial listing →
  • Terminated NCT NCT00399893

    Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)

    Not yet reported Duke University 5 participants Est. completion 2010-09 1 site Stand-alone
    Other conditions: Prader-Willi Syndrome
    View official trial listing →
  • Completed NCT NCT00412061

    Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

    Not yet reported Novartis Pharmaceuticals 429 participants Est. completion 2013-06 70 sites Stand-alone
    Other conditions: Carcinoid Tumor, Malignant Carcinoid Syndrome
    View official trial listing →
  • Completed NCT NCT00426153

    Octreotide in Severe Polycystic Liver Disease

    Not yet reported, Not yet reported Mayo Clinic 42 participants Est. completion 2008-10 1 site
    Other conditions: Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain
    View official trial listing →
  • Completed NCT NCT00427349

    AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

    Not yet reported Eastern Cooperative Oncology Group 46 participants Est. completion 2015-04 112 sites Stand-alone
    Other conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
    View official trial listing →
  • Completed NCT NCT00432068

    Open Label Study of a Single Dose of a New Extended Long Acting Formulation of Octreotide Pamoate in Healthy Volunteers

    Not yet reported Novartis Pharmaceuticals 48 participants Est. completion 2010-06 6 sites Stand-alone
    Other conditions: Healthy Cholecystectomized
    View official trial listing →
  • Completed NCT NCT00444873

    Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

    Not yet reported Ipsen 38 participants Est. completion 2008-01 1 site
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00461149

    Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly

    Not yet reported Federico II University 50 participants Est. completion 2006-12 1 site
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00463983

    Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide

    Not yet reported, Not yet reported Institut National de la Santé Et de la Recherche Médicale, France 25 participants Est. completion 2012-01 16 sites Stand-alone
    Other conditions: Idiopathic Pulmonary Fibrosis
    View official trial listing →
  • Terminated NCT NCT00466856

    Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

    Not yet reported Vanderbilt-Ingram Cancer Center 10 participants Est. completion 2007-10 1 site Stand-alone
    Other conditions: Head and Neck Cancer, Islet Cell Tumor, Metastatic Cancer, Pheochromocytoma
    View official trial listing →
  • Completed NCT NCT00495846

    GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma

    Not yet reported, Not yet reported Federico II University 25 participants Est. completion 2008-12 1 site Stand-alone
    Other conditions: Advanced Hepatocellular Carcinoma
    View official trial listing →
  • Terminated NCT NCT00510224

    Sandostatin for Patients With Androgen Independent Prostate Cancer

    Not yet reported University of California, San Francisco 13 participants Est. completion 2009-08 1 site
    Other conditions: Prostate Cancer
    View official trial listing →
  • Completed NCT NCT00521300

    Preoperative Octreotide Treatment of Acromegaly

    Not yet reported St. Olavs Hospital 62 participants Est. completion 2010-05 5 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00534677

    The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed

    Not yet reported Aga Khan University 320 participants Est. completion 2005-07 1 site
    Other conditions: Portal Hypertension, Cirrhosis, Hematemesis, Melena
    View official trial listing →
  • Completed NCT NCT00552071

    Ultrasound Guided Octreotide LAR Injection in Acromegaly

    Not yet reported Cedars-Sinai Medical Center 15 participants Est. completion 2014-03 1 site Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Active, not recruiting NCT NCT00569127

    Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

    Not yet reported National Cancer Institute (NCI) 427 participants Est. completion 2027-01-31 493 sites Stand-alone
    Other conditions: Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2
    View official trial listing →
  • Completed NCT NCT00582426

    Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea

    Not yet reported Novartis Pharmaceuticals 139 participants Est. completion 2010-09 11 sites Stand-alone
    Other conditions: Chemotherapy-induced Diarrhea
    View official trial listing →
  • Completed NCT NCT00584298

    Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide

    Not yet reported Novartis 50 participants 7 sites
    Other conditions: Irritable Bowel Syndrome (IBS)
    View official trial listing →
  • Completed NCT NCT00590343

    Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors

    Not yet reported Louisiana State University Health Sciences Center in New Orleans 23 participants Est. completion 2010-10 1 site
    Other conditions: Metastatic Neuroendocrine Tumors
    View official trial listing →
  • Completed NCT NCT00595140

    Acute Application of Pegvisomant and Octreotide in Acromegaly

    Not yet reported Ludwig-Maximilians - University of Munich 10 participants Est. completion 2008-03 1 site
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00600886

    Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

    Not yet reported Novartis Pharmaceuticals 358 participants Est. completion 2016-03-11 95 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00615004

    Cardiovascular Outcome After Surgery or Somatostatin Analogues

    Federico II University 215 participants Est. completion 2007-12 1 site
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00616408

    Prediction of Tumor Shrinkage in Acromegaly

    Federico II University 61 participants Est. completion 2007-12 1 site
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00616551

    Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients

    Not yet reported Ambrilia Biopharma, Inc. 65 participants Est. completion 2008-02 6 sites
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00635765

    Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

    Not yet reported Ambrilia Biopharma, Inc. 63 participants Est. completion 2009-06 6 sites
    Other conditions: Acromegaly
    View official trial listing →
  • Terminated NCT NCT00642421

    Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

    Not yet reported Ambrilia Biopharma, Inc. 40 participants Est. completion 2009-08 10 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00652379

    Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients

    Not yet reported University of Aarhus 18 participants Est. completion 2011-05 1 site Stand-alone
    Prediabetes Other conditions: Acromegaly, Insulin Resistance
    View official trial listing →
  • Completed NCT NCT00690430

    Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

    Not yet reported Novartis Pharmaceuticals 186 participants Est. completion 2012-04 62 sites
    Other conditions: Symptomatic Refractory Resistant Carcinoid Disease
    View official trial listing →
  • Completed NCT NCT00701363

    Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects

    Not yet reported Ipsen 124 participants Est. completion 2013-05 44 sites
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00703079

    Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly

    Federico II University 100 participants Est. completion 2008-06 1 site
    Other conditions: Acromegaly
    View official trial listing →
  • Terminated NCT NCT00742339

    Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome

    Not yet reported, Not yet reported University of Padova 49 participants Est. completion 2013-10 1 site Stand-alone
    Other conditions: Cirrhosis, Hepatorenal Syndrome
    View official trial listing →
  • Terminated NCT NCT00765323

    Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

    Not yet reported Endo USA Inc., a Keenova Therapeutics Company 169 participants Est. completion 2011-06 47 sites
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00781911

    A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

    Not yet reported Eli Lilly and Company 43 participants Est. completion 2016-05 10 sites Stand-alone
    Other conditions: Carcinoma, Neuroendocrine Tumors
    View official trial listing →
  • Completed NCT NCT00789841

    Gastrointestinal Motility in Patients With Neuroendocrine Tumors

    University of Aarhus 13 participants Est. completion 2010-05 1 site
    Other conditions: Neuroendocrine Tumor
    View official trial listing →
  • Completed NCT NCT00804297

    Octreotide for the Treatment of Sulfonylurea-Associated Hypoglycemia

    Not yet reported Albert Einstein Healthcare Network 40 participants Est. completion 2007-01 1 site
    Other conditions: Hypoglycemia, Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT00853047

    Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

    Not yet reported Lexicon Pharmaceuticals 23 participants Est. completion 2014-06 9 sites Stand-alone
    Other conditions: Carcinoid Syndrome
    View official trial listing →
  • Terminated NCT NCT00884715

    Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome

    Not yet reported, Not yet reported Endo USA Inc., a Keenova Therapeutics Company 10 participants Est. completion 2011-12 3 sites Stand-alone
    Other conditions: Carcinoid Syndrome
    View official trial listing →
  • Completed NCT NCT00913055

    Open Label Study of Octreotide Implant in Patients With Acromegaly

    Not yet reported Endo USA Inc., a Keenova Therapeutics Company 34 participants Est. completion 2007-05 Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT00953394

    5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors

    Not yet reported University of Turin, Italy 29 participants Est. completion 2006-12 7 sites Stand-alone
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Completed NCT NCT00966355

    Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding

    Not yet reported Korea University 1034 participants Est. completion 2010-05 1 site
    Other conditions: Variceal Bleeding, Cirrhosis
    View official trial listing →
  • Completed NCT NCT00978211

    DOTA-TOC in Metastasized Neuroendocrine Tumors

    Not yet reported University Hospital, Basel, Switzerland 1499 participants Est. completion 2013-12 1 site
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Completed NCT NCT00987168

    Sandostatine® LP and Hyperinsulinism

    Not yet reported Assistance Publique - Hôpitaux de Paris 10 participants Est. completion 2011-06 1 site
    Other conditions: Congenital Hyperinsulinism
    View official trial listing →
  • Completed NCT NCT00990535

    High Dose Somatostatin Analogues in Neuroendocrine Tumors

    Not yet reported Federico II University 28 participants Est. completion 2008-12 1 site Stand-alone
    Other conditions: Respiratory Tract Neoplasms, Thymic Neoplasms, Pancreatic Neoplasms, Gastrointestinal Neoplasms, Multiple Endocrine Neoplasia
    View official trial listing →
  • Completed NCT NCT01014793

    Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients

    Federal University of São Paulo 19 participants Est. completion 2008-12 1 site
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT01029275

    Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone

    Not yet reported University Hospital, Rouen 89 participants Est. completion 2012-01 13 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Withdrawn NCT NCT01048086

    90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

    Not yet reported University of Iowa Est. completion 2013-11 1 site
    Other conditions: Neuroblastoma, Neuroendocrine Tumor
    View official trial listing →
  • Completed NCT NCT01070758

    Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy

    Not yet reported Sheba Medical Center 3 participants Est. completion 2015-02 1 site Stand-alone
    Other conditions: Congenital Hyperinsulinism
    View official trial listing →
  • Suspended NCT NCT01086982

    Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®

    Not yet reported Azidus Brasil 16 participants Est. completion 2010-05 1 site Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT01121939

    Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

    Not yet reported SCRI Development Innovations, LLC 43 participants Est. completion 2015-08 9 sites
    Other conditions: Neuroendocrine Carcinoma
    View official trial listing →
  • Completed NCT NCT01137682

    Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

    Not yet reported Novartis Pharmaceuticals 198 participants Est. completion 2017-02-28 60 sites
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT01157858

    Everolimus and LongActing Octreotide Trial in Polycystic Livers

    Not yet reported Radboud University Medical Center 44 participants Est. completion 2012-07 1 site
    Other conditions: Polycystic Liver Disease
    View official trial listing →
  • Completed NCT NCT01188733

    Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis

    Not yet reported, Not yet reported Mayo Clinic 39 participants Est. completion 2000-12 Stand-alone
    Other conditions: Cirrhosis, Portal Hypertension, Esophageal Varices
    View official trial listing →
  • Status unknown NCT NCT01203306

    Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors

    Not yet reported University of Turin, Italy 42 participants Est. completion 2010-12 5 sites Stand-alone
    Other conditions: Neuroendocrine Carcinomas
    View official trial listing →
  • Completed NCT NCT01204476

    Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

    Not yet reported National Cancer Institute (NCI) 27 participants 1 site Stand-alone
    Other conditions: Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Paraganglioma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Merkel Cell Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor, Stage III Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma, Thyroid Gland Medullary Carcinoma
    View official trial listing →
  • Completed NCT NCT01229943

    Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

    Not yet reported National Cancer Institute (NCI) 150 participants Est. completion 2018-01-03 394 sites Stand-alone
    Other conditions: Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Pancreatic Gastrinoma, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2, Pancreatic Vipoma
    View official trial listing →
  • Completed NCT NCT01267669

    A Trial of Somatostatin With Endoscopic Variceal Ligation (EVL) in Control of Acute Variceal Bleeding

    Not yet reported Govind Ballabh Pant Hospital 61 participants Est. completion 2009-11 1 site
    Other conditions: Acute Bleeding Esophageal Varices, Portal Hypertension, Cirrhosis
    View official trial listing →
  • Completed NCT NCT01278342

    Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients

    Not yet reported Novartis Pharmaceuticals 70 participants Est. completion 2009-11 20 sites
    Other conditions: Acromegaly
    View official trial listing →
  • Terminated NCT NCT01295060

    Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly

    Not yet reported Endo USA Inc., a Keenova Therapeutics Company 12 participants Est. completion 2012-06 6 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT01301222

    Role of Octreotide in Preventing Pancreatic Fistula After Pancreaticoduodenectomy (PD) in Patients With Soft Pancreas

    Not yet reported PVS Memorial Hospital 110 participants Est. completion 2015-02 1 site Stand-alone
    Other conditions: Pancreatic Fistula
    View official trial listing →
  • Completed NCT NCT01346098

    Islet Autotransplantation in Patients at Very High-risk Pancreatic Anastomosis

    Not yet reported Ospedale San Raffaele 60 participants Est. completion 2019-04 1 site
    Other conditions: Postpancreatectomy Hyperglycemia
    View official trial listing →
  • Completed NCT NCT01370161

    Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for Acute Variceal Bleeding in Patients With Advanced Cirrhosis

    Not yet reported Air Force Military Medical University, China 132 participants Est. completion 2018-09-30 1 site Stand-alone
    Other conditions: Decompensated Cirrhosis, Bleeding Varices
    View official trial listing →
  • Completed NCT NCT01371643

    Surgical Debulking of Pituitary Adenomas

    Not yet reported NYU Langone Health 41 participants Est. completion 2011-12 1 site
    Other conditions: Pituitary Adenoma
    View official trial listing →
  • Completed NCT NCT01377246

    Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency

    Not yet reported Mario Negri Institute for Pharmacological Research 100 participants Est. completion 2017-10-18 6 sites Stand-alone
    Other conditions: Autosomal Dominant Polycystic Kidney Disease
    View official trial listing →
  • Completed NCT NCT01400100

    Effects of Intraarterial Octreotide on Pancreatic Texture

    Not yet reported St. Josef Hospital Bochum 26 participants Est. completion 2012-03 1 site Stand-alone
    Other conditions: Pancreatic Fistula
    View official trial listing →
  • Completed NCT NCT01412424

    Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly

    Not yet reported Chiasma, Inc. 155 participants Est. completion 2014-05 36 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT01424241

    Effects of Sandostatin LAR® in Acromegaly

    Not yet reported Columbia University 21 participants Est. completion 2014-01 1 site
    Other conditions: Acromegaly
    View official trial listing →
  • Terminated NCT NCT01469338

    Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

    Not yet reported University of Southern California 9 participants Est. completion 2014-11 1 site Stand-alone
    Other conditions: Diarrhea, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
    View official trial listing →
  • Completed NCT NCT01480986

    IPO-NEC Trial:Study on the Efficacy and Safety Using Sequential IP Therapy and Oct Lar in the Treatment of Advanced GI NEC

    Not yet reported Peking University 40 participants Est. completion 2013-12 1 site Stand-alone
    Other conditions: Progression Free Survival of the Treatment
    View official trial listing →
  • Terminated NCT NCT01538966

    Acromegaly Combination Treatment Study

    Not yet reported Cedars-Sinai Medical Center 76 participants Est. completion 2022-05-20 1 site
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT01561066

    Autologous Fibrin Glues for Fistulas Closure

    Not yet reported Jinling Hospital, China 122 participants Est. completion 2012-01 1 site
    Other conditions: Enterocutaneous Fistulas, Intra-abdominal Infection
    View official trial listing →
  • Completed NCT NCT01567488

    Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET

    Not yet reported Grupo Espanol de Tumores Neuroendocrinos 43 participants Est. completion 2017-06-07 1 site Stand-alone
    Other conditions: Gastrointestinal Neoplasms
    View official trial listing →
  • Completed NCT NCT01578239

    A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

    Not yet reported Advanced Accelerator Applications 231 participants Est. completion 2021-01-18 39 sites Stand-alone
    Other conditions: Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour
    View official trial listing →
  • Withdrawn NCT NCT01587222

    Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure

    Not yet reported Anna Cruceta Est. completion 2017-08 1 site Stand-alone
    Other conditions: Fibrosis, Renal Failure, Hepatorenal Syndrome
    View official trial listing →
  • Status unknown NCT NCT01613495

    Ghrelin Suppression by Octreotide in Prader-Willi

    Not yet reported Oregon Health and Science University 2 participants Est. completion 2024-11
    Other conditions: Prader Willis Syndrome
    View official trial listing →
  • Completed NCT NCT01618513

    Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target

    Not yet reported University of Aarhus 84 participants Est. completion 2017-01 1 site
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT01619865

    Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors

    Not yet reported, Not yet reported Sue O'Dorisio 223 participants Est. completion 2017-08-27 1 site
    Other conditions: Neuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma, Medulloblastoma
    View official trial listing →
  • Completed NCT NCT01673906

    68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours

    Not yet reported Azienda USL Reggio Emilia - IRCCS 142 participants Est. completion 2016-07-05 21 sites Stand-alone
    Other conditions: Neuroendocrine Tumours
    View official trial listing →
  • Completed NCT NCT01677910

    TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

    Not yet reported Lexicon Pharmaceuticals 135 participants Est. completion 2016-03-21 75 sites Stand-alone
    Other conditions: Carcinoid Syndrome
    View official trial listing →
  • Completed NCT NCT01707225

    Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)

    Not yet reported Virginia Commonwealth University 10 participants Est. completion 2014-10 1 site Stand-alone
    Other conditions: Gastrointestinal Bleeding
    View official trial listing →
  • Completed NCT NCT01744249

    Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

    Not yet reported, Not yet reported Grupo Espanol de Tumores Neuroendocrinos 256 participants Est. completion 2023-12-31 26 sites
    Other conditions: Neuroendocrine Tumors, Advanced Cancer
    View official trial listing →
  • Completed NCT NCT01754285

    Extended-release of Octreotide (LF-PB) for the Treatment of Lymphorrhea

    Not yet reported Chemi S.p.A. 114 participants Est. completion 2014-05 13 sites
    Other conditions: Lymphorrhea
    View official trial listing →
  • Terminated NCT NCT01755182

    Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors

    Not yet reported National Cancer Institute, Naples 1 participants Est. completion 2016-03 12 sites
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Completed NCT NCT01783899

    Clinical Evaluation of Hemospray in Hemostasis of Active Variceal Bleeding

    Not yet reported Theodor Bilharz Research Institute 30 participants Est. completion 2014-06 2 sites Stand-alone
    Other conditions: Variceal Hemorrhage
    View official trial listing →
  • Completed NCT NCT01789281

    Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

    Not yet reported Novartis Pharmaceuticals 34 participants Est. completion 2020-08-28 24 sites
    Other conditions: Neoplasms
    View official trial listing →
  • Withdrawn NCT NCT01860742

    Randomized Phase III of PRRT Versus Interferon

    Not yet reported Jules Bordet Institute Est. completion 2016-10 2 sites
    Other conditions: Gastro-intestinal Neuroendocrine Tumors
    View official trial listing →
  • Completed NCT NCT01865760

    Etiology, Assessment and Treatment of Post-gastric Bypass Severe Hypoglycemia

    Not yet reported University of Aarhus 33 participants Est. completion 2016-03 1 site Stand-alone
    Other conditions: Obesity, Hypoglycemia, Surgery
    View official trial listing →
  • Completed NCT NCT01869725

    Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

    Not yet reported Sue O'Dorisio 68 participants Est. completion 2018-12-26 1 site
    Other conditions: Adult Medulloblastoma, Childhood Medulloblastoma, Neuroblastoma, Neuroendocrine Tumor, Somatostatinoma
    View official trial listing →
  • Completed NCT NCT01871844

    ITF2984 Repeated Doses Study in Healthy Volunteers

    Not yet reported Italfarmaco 46 participants Est. completion 2013-05 2 sites
    Other conditions: Healthy Male Volunteers
    View official trial listing →
  • Terminated NCT NCT01886287

    P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 2 participants Est. completion 2014-10 1 site Stand-alone
    Other conditions: Neuroendocrine Carcinoma
    View official trial listing →
  • Completed NCT NCT01917773

    Effect of Octreotide on the Colonic Motility in Pediatric Patients

    Not yet reported Indiana University 13 participants Est. completion 2014-06 1 site Stand-alone
    Other conditions: Colonic Motility Index, Constipation
    View official trial listing →
  • Completed NCT NCT02010385

    Investigation of the Effects of Obesity Surgery on Appetitive Behaviour

    Not yet reported University College Dublin 30 participants Est. completion 2018-06 1 site
    Other conditions: Roux-en-Y Bariatric Surgery
    View official trial listing →
  • Completed NCT NCT02012166

    A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)

    Not yet reported Merck Sharp & Dohme LLC 18 participants Est. completion 2005-12
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT02021942

    Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size

    Not yet reported Prof. Dr. Berthold Schalke 16 participants Est. completion 2015-10 1 site
    Other conditions: Primary Inoperable Thymoma, Local Recurrent Thymoma
    View official trial listing →
  • Terminated NCT NCT02032784

    Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding

    Not yet reported AdventHealth 33 participants Est. completion 2020-07-06 1 site Stand-alone
    Other conditions: Adenoma
    View official trial listing →
  • Completed NCT NCT02111044

    Phase II Study With ITF2984 in Acromegalic Patients

    Not yet reported Italfarmaco 48 participants Est. completion 2016-02 26 sites
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT02119884

    Hemodynamic Effects of Terlipressin and High Dose Octreotide

    Not yet reported Shanghai Zhongshan Hospital 88 participants Est. completion 2016-06 1 site
    Other conditions: Gastric and Esophageal Varices
    View official trial listing →
  • Terminated NCT NCT02123576

    Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline

    Not yet reported Patrick Northup, MD 12 participants Est. completion 2017-12-31 1 site Stand-alone
    Other conditions: Hepatorenal Syndrome
    View official trial listing →
  • Status unknown NCT NCT02147470

    Evaluation of Renal Blood Flow Using Contrast Enhanced Ultrasound for Differential Diagnosis of Acute Kidney Injury in Cirrhotic Patients: A Pilot Study

    Not yet reported University of Virginia 25 participants 1 site
    Other conditions: Liver Cirrhosis and Acute Kidney Injury
    View official trial listing →
  • Terminated NCT NCT02177773

    GA-68 DOTA-TOC of Somatostatin Positive Malignancies

    Not yet reported, Not yet reported University of California, San Francisco 300 participants Est. completion 2017-08-07 1 site
    Other conditions: Neuroendocrine Tumor, Paraganglioma, Carcinoid Tumors, Neuroblastoma
    View official trial listing →
  • Withdrawn NCT NCT02194452

    Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors

    Not yet reported Sue O'Dorisio Est. completion 2017-03 1 site
    Obstructive sleep apnea Other conditions: Acoustic Schwannoma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Choroid Plexus Tumor, Adult Craniopharyngioma, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Medulloblastoma, Adult Meningeal Hemangiopericytoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Pineoblastoma, Adult Pineocytoma, Adult Subependymal Giant Cell Astrocytoma, Adult Subependymoma, Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Low-grade Cerebellar Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Childhood Supratentorial Ependymoma, Meningeal Melanocytoma, Newly Diagnosed Childhood Ependymoma, Recurrent Adult Brain Tumor, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Diffuse Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Fibrillary Astrocytoma, Recurrent Childhood Gemistocytic Astrocytoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Medulloblastoma, Recurrent Childhood Oligoastrocytoma, Recurrent Childhood Oligodendroglioma, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Pilomyxoid Astrocytoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Pleomorphic Xanthoastrocytoma, Recurrent Childhood Protoplasmic Astrocytoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Cerebellar Astrocytoma, Untreated Childhood Cerebral Astrocytoma, Untreated Childhood Diffuse Astrocytoma, Untreated Childhood Fibrillary Astrocytoma, Untreated Childhood Gemistocytic Astrocytoma, Untreated Childhood Giant Cell Glioblastoma, Untreated Childhood Glioblastoma, Untreated Childhood Gliomatosis Cerebri, Untreated Childhood Medulloblastoma, Untreated Childhood Oligoastrocytoma, Untreated Childhood Oligodendroglioma, Untreated Childhood Pilocytic Astrocytoma, Untreated Childhood Pilomyxoid Astrocytoma, Untreated Childhood Pineoblastoma, Untreated Childhood Pleomorphic Xanthoastrocytoma, Untreated Childhood Protoplasmic Astrocytoma, Untreated Childhood Subependymal Giant Cell Astrocytoma, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor, Untreated Childhood Visual Pathway and Hypothalamic Glioma, Untreated Childhood Visual Pathway Glioma
    View official trial listing →
  • Completed NCT NCT02195635

    Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects

    Not yet reported Lexicon Pharmaceuticals 24 participants 1 site
    Other conditions: Drug Interactions
    View official trial listing →
  • Completed NCT NCT02217800

    The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics

    Not yet reported Aspireo Pharmaceuticals Limited 8 participants Est. completion 2016-05
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT02217826

    Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173

    Not yet reported Aspireo Pharmaceuticals Limited 8 participants Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02217839

    Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173

    Not yet reported Aspireo Pharmaceuticals Limited 42 participants Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02235987

    Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.

    Not yet reported Aspireo Pharmaceuticals Limited 20 participants Est. completion 2014-04
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT02237053

    Effects of Glucagon Administration on Energy Expenditure

    Not yet reported AdventHealth Translational Research Institute 6 participants Est. completion 2016-06 1 site
    Other conditions: Hyperglucagonemia, Obesity
    View official trial listing →
  • Status unknown NCT NCT02294006

    Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs

    Not yet reported Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 26 participants Est. completion 2021-10 1 site Stand-alone
    Other conditions: Well Differentiated Pancreatic Endocrine Tumor
    View official trial listing →
  • Terminated NCT NCT02294786

    Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

    Not yet reported Novartis Pharmaceuticals 62 participants Est. completion 2017-10-19 17 sites Stand-alone
    Other conditions: Cancer
    View official trial listing →
  • Completed NCT NCT02299089

    Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

    Not yet reported Camurus AB 12 participants Est. completion 2016-06 10 sites Stand-alone
    Other conditions: Acromegaly, Neuroendocrine Tumors
    View official trial listing →
  • Completed NCT NCT02305069

    Effect of Obesity-derived Cytokines on Protein Turnover and Carbohydrate Metabolism in Human Skeletal Muscle

    Not yet reported University of Nottingham 26 participants Est. completion 2012-09 1 site Stand-alone
    Other conditions: Obesity, Sarcopenia
    View official trial listing →
  • Status unknown NCT NCT02311608

    Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails

    Shanghai Zhongshan Hospital 1320 participants Est. completion 2016-06 1 site
    Other conditions: Liver Cirrhosis, Esophageal and Gastric Varices, Hemorrhage
    View official trial listing →
  • Completed NCT NCT02333565

    Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas

    Not yet reported Assistance Publique Hopitaux De Marseille 20 participants Est. completion 2023-05-24 1 site Stand-alone
    Other conditions: Recurrent Meningiomas, Resistant Meningiomas
    View official trial listing →
  • Completed NCT NCT02335580

    Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis

    General Hospital of Shenyang Military Region 475 participants Est. completion 2022-12 1 site
    Other conditions: Liver Cirrhosis, Portal Vein, Venous Thrombosis, Varicose Veins, Hemorrhage
    View official trial listing →
  • Terminated NCT NCT02359500

    68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)

    Not yet reported Lale Kostakoglu 71 participants Est. completion 2017-01-23 1 site
    Other conditions: Neuroendocrine Tumors, Carcinoid Tumors
    View official trial listing →
  • Status unknown NCT NCT02374632

    Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass

    Not yet reported Hvidovre University Hospital 40 participants Est. completion 2017-06 1 site
    Other conditions: Bariatric Surgery (Gastric Bypass), Severe Obesity
    View official trial listing →
  • No Longer Available NCT NCT02375464

    Gallium-68 DOTATOC for Management of Neuroendocrine Tumors

    Northwell Health Est. completion 2019-12
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Completed NCT NCT02381249

    The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery

    Not yet reported St. James's Hospital, Ireland 40 participants Est. completion 2018-03 2 sites Stand-alone
    Other conditions: Esophageal Neoplasms, Stomach Neoplasms, Weight Loss, Malnutrition, Pancreatic Neoplasms, Duodenal Neoplasms
    View official trial listing →
  • Completed NCT NCT02384122

    Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias

    Not yet reported Radboud University Medical Center 62 participants Est. completion 2023-05 12 sites
    Other conditions: Angiodysplasia, Vascular Malformations, Gastrointestinal Hemorrhage, Anemia
    View official trial listing →
  • Completed NCT NCT02385617

    Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer

    Not yet reported St. James's Hospital, Ireland 20 participants Est. completion 2017-12 2 sites Stand-alone
    Other conditions: Esophageal Neoplasms, Stomach Neoplasms, Weight Loss, Malnutrition
    View official trial listing →
  • Completed NCT NCT02396953

    Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

    Not yet reported, Not yet reported Ipsen 28 participants Est. completion 2017-11-28 36 sites
    Other conditions: Acromegaly
    View official trial listing →
  • Status unknown NCT NCT02409849

    Octreotide LAR as Maintenance Treatment for Patients With NEC

    Not yet reported Peking University 92 participants Est. completion 2019-06 1 site Stand-alone
    Other conditions: Gastro-entero-pancreatic Carcinoma, Esophageal Neuroendocrine Carcinoma
    View official trial listing →
  • Status unknown NCT NCT02427295

    Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues

    Not yet reported Asan Medical Center 1 participants Est. completion 2019-12 1 site Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Status unknown NCT NCT02437825

    Octreotide VS Placebo in Prevention of Salivary Fistulae After Post Radiation Salvage Surgery

    Not yet reported Hadassah Medical Organization 40 participants Est. completion 2021-06 1 site Stand-alone
    Other conditions: Fistula; Salivary Duct or Gland
    View official trial listing →
  • Completed NCT NCT02457156

    Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy

    Not yet reported University of Liverpool 295 participants Est. completion 2019-01-31 1 site Stand-alone
    Other conditions: Pancreatic Cancer
    View official trial listing →
  • Completed NCT NCT02474914

    Octreotide in the Prevention of Postoperative Complications After Pancreaticoduodenectomy

    Not yet reported Mansoura University 104 participants Est. completion 2017-04 1 site
    Other conditions: Periampullary Carcinoma Resectable
    View official trial listing →
  • Terminated NCT NCT02488512

    Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas

    Not yet reported Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 1 participants Est. completion 2018-02-23 1 site
    Other conditions: DLBCL, MCL, Recurrent Disease
    View official trial listing →
  • Status unknown NCT NCT02631616

    Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET

    Not yet reported Hadassah Medical Organization 30 participants Est. completion 2018-03
    Other conditions: Prostatic Neoplasms
    View official trial listing →
  • Status unknown NCT NCT02668172

    Pasireotide LAR and Pegvisomant Study in Acromegaly

    Not yet reported Erasmus Medical Center 60 participants Est. completion 2017-06 1 site Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT02668588

    Extended-release of Octreotide (LF-PB) for the Treatment of Seroma

    Not yet reported Chemi S.p.A. 48 participants Est. completion 2016-07-19 7 sites Stand-alone
    Other conditions: Seroma
    View official trial listing →
  • Completed NCT NCT02685709

    Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

    Not yet reported Chiasma, Inc. 146 participants Est. completion 2021-08 53 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT02691078

    Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors

    Not yet reported Latin American Cooperative Oncology Group 15 participants Est. completion 2018-01-10 1 site Stand-alone
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Terminated NCT NCT02736448

    177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors

    Not yet reported Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 35 participants Est. completion 2023-04-30 1 site Stand-alone
    Other conditions: Gastro-entero-pancreatic Neuroendocrine Tumors
    View official trial listing →
  • Completed NCT NCT02795858

    A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

    Not yet reported Dana-Farber Cancer Institute 43 participants Est. completion 2023-12-31 2 sites
    Other conditions: Carcinoid Tumors
    View official trial listing →
  • Status unknown NCT NCT02874326

    Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber

    Not yet reported Radboud University Medical Center 15 participants Est. completion 2018-10 2 sites Stand-alone
    Other conditions: Hereditary Hemorrhagic Telangiectasia, Gastrointestinal Hemorrhage, Anemia
    View official trial listing →
  • Completed NCT NCT02916433

    Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients

    Not yet reported Danbury Hospital 5 participants Est. completion 2019-02 1 site Stand-alone
    Other conditions: Octreotide, Sputum
    View official trial listing →
  • Status unknown NCT NCT02920567

    Impact of Prophylactic Octreotide to Pancreatic Exocrine Secretion

    Not yet reported Saint Vincent's Hospital, Korea 282 participants Est. completion 2018-07 1 site Stand-alone
    Other conditions: Periampullary Tumors
    View official trial listing →
  • Completed NCT NCT02973204

    Circulating Tumor Cells and Tumor DNA in HCC and NET

    University of Aarhus 167 participants Est. completion 2020-01-08 1 site
    Other conditions: Carcinoma, Hepatocellular, Neuroendocrine Tumors
    View official trial listing →
  • Status unknown NCT NCT02977897

    Fecal Calprotectin Levels in Mycophenolate Mofetil Induced Diarrhea and Treatment With Octreotide

    University Health Network, Toronto 10 participants 1 site
    Other conditions: Diarrhea, Immunosuppression
    View official trial listing →
  • Completed NCT NCT03000946

    Prevention of Postoperative Pancreatic Fistula by Somatostatin

    Not yet reported Assistance Publique - Hôpitaux de Paris 655 participants Est. completion 2021-02-09 2 sites
    Other conditions: Pancreatic Surgery
    View official trial listing →
  • Terminated NCT NCT03001349

    68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

    Not yet reported M.D. Anderson Cancer Center 4 participants Est. completion 2021-02-05 1 site
    Other conditions: Meningioma, Metastatic Well Differentiated Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia Type 1, Neuroendocrine Neoplasm, Somatostatin Positive Neoplastic Cells Present, Von Hippel-Lindau Syndrome
    View official trial listing →
  • Withdrawn NCT NCT03013387

    Dosimetry Guided PRRT With 90Y-DOTATOC

    Not yet reported Sue O'Dorisio Est. completion 2019-10 Stand-alone
    Other conditions: Neuroendrocrine Tumors, Meningioma, Neuroblastoma, Medulloblastoma
    View official trial listing →
  • Completed NCT NCT03017690

    Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

    Ipsen 22 participants Est. completion 2018-05-30 5 sites
    Other conditions: Gastroenteropancreatic Neuroendocrine Tumor
    View official trial listing →
  • Completed NCT NCT03031535

    Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers

    Not yet reported Dauntless Pharmaceuticals 32 participants Est. completion 2017-03 1 site Stand-alone
    Other conditions: Healthy Volunteer Study
    View official trial listing →
  • Active, not recruiting NCT NCT03044977

    Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

    Not yet reported David Bushnell 20 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Neuroendocrine Tumor, Malignant, Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
    View official trial listing →
  • Active, not recruiting NCT NCT03049189

    Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

    Not yet reported ITM Solucin GmbH 324 participants Est. completion 2029-11 52 sites
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Withdrawn NCT NCT03057509

    A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors

    Not yet reported Massachusetts General Hospital Est. completion 2021-09-30 2 sites Stand-alone
    Other conditions: Small Bowel Carcinoid Tumor
    View official trial listing →
  • Completed NCT NCT03061604

    RCT to Determine the Efficacy of Combining Hemospray With Medical Treatment in Acute Variceal Bleeding

    Not yet reported Theodor Bilharz Research Institute 105 participants Est. completion 2017-11 2 sites Stand-alone
    Other conditions: Variceal Hemorrhage
    View official trial listing →
  • Completed NCT NCT03103009

    Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia

    Not yet reported University of Colorado, Denver 1 participants Est. completion 2017-12-22 1 site Stand-alone
    Other conditions: Hyperinsulinemic Hypoglycemia, Post Gastrointestinal Tract Surgery Hypoglycaemia
    View official trial listing →
  • Completed NCT NCT03112694

    Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

    Ipsen 93 participants Est. completion 2017-11-02 8 sites
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Terminated NCT NCT03179995

    Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy

    Not yet reported Fox Chase Cancer Center 23 participants Est. completion 2020-02-12 2 sites Stand-alone
    Other conditions: Major Liver Resection
    View official trial listing →
  • Completed NCT NCT03197012

    Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

    Not yet reported Thomas Hope 10 participants Est. completion 2019-05-31 1 site
    Other conditions: Neuroendocrine Tumor
    View official trial listing →
  • Status unknown NCT NCT03252353

    Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

    Not yet reported Chiasma, Inc. 56 participants Est. completion 2022-05 60 sites
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT03273712

    Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

    Not yet reported University of Iowa 39 participants Est. completion 2020-05-27 1 site Stand-alone
    Other conditions: Neuroendocrine Tumors, Meningioma, Neuroblastoma, Medulloblastoma
    View official trial listing →
  • Completed NCT NCT03289741

    A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

    Not yet reported Memorial Sloan Kettering Cancer Center 51 participants Est. completion 2023-04-10 7 sites Stand-alone
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Terminated NCT NCT03377660

    Resection of the Esophagus and Subsequent Weight Loss

    Imperial College London 30 participants Est. completion 2023-06-01 1 site
    Other conditions: Esophageal Cancer, Weight Gain, Eating Behavior, Food Reward
    View official trial listing →
  • Status unknown NCT NCT03398941

    The Effect of Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide on the Complications After Pancreatectomy. A Prospective, Multicenter Clinical Trial

    Not yet reported Chengfeng Wang 150 participants Est. completion 2019-05-01 1 site Stand-alone
    Other conditions: Pancreatic Diseases
    View official trial listing →
  • Completed NCT NCT03455322

    Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1.

    Not yet reported National Hepatology & Tropical Medicine Research Institute 60 participants Est. completion 2020-07-10 1 site
    Other conditions: Renal Impairment in Hepatorenal Syndrome
    View official trial listing →
  • Terminated NCT NCT03466216

    Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET

    Not yet reported Orano Med LLC 33 participants Est. completion 2023-04-06 1 site
    Other conditions: Neuroendocrine Tumor
    View official trial listing →
  • Status unknown NCT NCT03511768

    A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms

    Not yet reported, Not yet reported Xiangya Hospital of Central South University 65 participants Est. completion 2020-12-30 1 site Stand-alone
    Other conditions: Neuroendocrine Neoplasm
    View official trial listing →
  • Completed NCT NCT03520569

    Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults

    Not yet reported University of Virginia 15 participants Est. completion 2021-04-01 1 site
    Other conditions: Vascular Stiffness, Insulin Sensitivity
    View official trial listing →
  • Completed NCT NCT03541447

    Tolvaptan-Octreotide LAR Combination in ADPKD

    Not yet reported Mario Negri Institute for Pharmacological Research 20 participants Est. completion 2021-12-23 1 site Stand-alone
    Other conditions: Autosomal Dominant Polycystic Kidney Disease
    View official trial listing →
  • Terminated NCT NCT03571594

    A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers

    Not yet reported Ono Pharmaceutical Co., Ltd. 76 participants Est. completion 2019-05-16 1 site Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Terminated NCT NCT03624517

    Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices

    Not yet reported Medical University of South Carolina 34 participants Est. completion 2024-12-01 8 sites Stand-alone
    Other conditions: Esophageal Varices, Liver Cirrhoses, Bleeding Esophageal Varices, Upper Gastrointestinal Bleeding
    View official trial listing →
  • Terminated NCT NCT03724409

    Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases

    Not yet reported Sandeep Laroia 3 participants Est. completion 2023-05-23 1 site
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Completed NCT NCT03734627

    Gastrointestinal Nutrient Transit and Enteroendocrine Function After Upper Gastrointestinal Surgery

    St. James's Hospital, Ireland 40 participants Est. completion 2021-07-01 2 sites
    Other conditions: Esophageal Cancer, Nutrition Disorders, Appetite Disorders, Dumping Syndrome, Delayed Gastric Emptying, Surgery
    View official trial listing →
  • Status unknown NCT NCT03741517

    Biomarker Study of Pancreatic Neuroendocrine Tumours

    Uppsala University 40 participants Est. completion 2024-12-31 1 site
    Other conditions: Pancreatic Neuroendocrine Tumor
    View official trial listing →
  • Status unknown NCT NCT03756116

    Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide

    Not yet reported The Second Hospital of Nanjing Medical University 2000 participants Est. completion 2020-10-01 1 site
    Other conditions: Post-ERCP Acute Pancreatitis, Epinephrine
    View official trial listing →
  • Terminated NCT NCT03791736

    Evaluation of Impact of Sandostatin® Injection Before Axillary Clearance on Lymphocele Formation

    Not yet reported Institut Cancerologie de l'Ouest 4 participants Est. completion 2018-07-06
    Other conditions: Breast Cancer, Lymphocele
    View official trial listing →
  • Completed NCT NCT03792555

    A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)

    Not yet reported Crinetics Pharmaceuticals Inc. 13 participants Est. completion 2020-08-12 11 sites
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT03798912

    A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform

    Not yet reported RANI Therapeutics 62 participants Est. completion 2020-02-17 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Status unknown NCT NCT03812939

    Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs

    Peking Union Medical College Hospital 30 participants Est. completion 2020-12-31 1 site
    Other conditions: Gastric NET
    View official trial listing →
  • Completed NCT NCT03846180

    Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage

    General Hospital of Shenyang Military Region 1682 participants Est. completion 2019-07-01 14 sites
    Other conditions: Variceal Hemorrhage, Cirrhosis, Liver, Kidney Injury
    View official trial listing →
  • Completed NCT NCT03879694

    Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

    Not yet reported Roswell Park Cancer Institute 19 participants Est. completion 2025-03-14 1 site Stand-alone
    Other conditions: Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor, Metastatic Pancreatic Neuroendocrine Tumor
    View official trial listing →
  • Completed NCT NCT03883776

    Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors

    Not yet reported Universitaire Ziekenhuizen KU Leuven 12 participants Est. completion 2019-10-29 1 site Stand-alone
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Withdrawn NCT NCT03891849

    Macro and Microcirculatory Effects of the Combination of Norepinephrine and Octreotide for the Treatment of Cirrhotic Patients With Hemorrhagic Shock

    Not yet reported Centre Hospitalier Universitaire, Amiens Est. completion 2023-05 1 site Stand-alone
    Other conditions: Haemorrhagic Shock, Variceal Hemorrhage
    View official trial listing →
  • Completed NCT NCT03967249

    Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

    Not yet reported Ionis Pharmaceuticals, Inc. 39 participants Est. completion 2022-07-07 22 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Active, not recruiting NCT NCT03972488

    Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

    Not yet reported Advanced Accelerator Applications 226 participants Est. completion 2027-10-29 40 sites Stand-alone
    Other conditions: Gastro-enteropancreatic Neuroendocrine Tumor
    View official trial listing →
  • Terminated NCT NCT04027348

    Palliative Management of Inoperable Malignant Bowel Obstruction

    Not yet reported Roswell Park Cancer Institute 15 participants Est. completion 2021-09-03 1 site Stand-alone
    Other conditions: Malignant Bowel Obstruction
    View official trial listing →
  • Status unknown NCT NCT04028323

    Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903)

    Not yet reported Nanfang Hospital, Southern Medical University 60 participants Est. completion 2022-10-15 10 sites
    Other conditions: Renal Function Disorder, Acute Variceal Bleeding
    View official trial listing →
  • Withdrawn NCT NCT04048707

    Angiotensin 2 for Hepatorenal Syndrome

    Not yet reported University of California, Los Angeles Est. completion 2023-07-01
    Other conditions: Hepatorenal Syndrome, Cirrhosis, Kidney Failure, Acute
    View official trial listing →
  • Completed NCT NCT04076462

    A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

    Not yet reported Camurus AB 72 participants Est. completion 2023-05-02 63 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT04125836

    A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

    Not yet reported Camurus AB 135 participants Est. completion 2025-04-24 68 sites Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Completed NCT NCT04129255

    Octreotide LAR in the Induction of Immunologic Response in NENs Patients

    Not yet reported National Cancer Institute, Naples 34 participants Est. completion 2019-12-01 1 site
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Terminated NCT NCT04140409

    Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation

    Not yet reported Cliniques universitaires Saint-Luc- Université Catholique de Louvain 10 participants Est. completion 2019-09-19 Stand-alone
    Other conditions: Neuroendocrine Tumors, Carcinoid Syndrome
    View official trial listing →
  • Status unknown NCT NCT04194125

    Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer

    Not yet reported University of Warmia and Mazury 25 participants Est. completion 2022-01-31 1 site
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Withdrawn NCT NCT04276597

    Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

    Not yet reported Excel Diagnostics and Nuclear Oncology Center Est. completion 2021-07-15 1 site
    Other conditions: Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma, Thymus Carcinoid, Unknown Primary Tumors, Neuroendocrine Tumors, Neuroendocrine Skin Carcinoma, Neuroendocrine Breast Tumor, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Neoplasm of Ovary
    View official trial listing →
  • Completed NCT NCT04281680

    Impact of Pasireotide on Postoperative Pancreatic Fistulas Following Distal Resections

    Helsinki University Central Hospital 258 participants Est. completion 2016-04-30
    Other conditions: Surgical Complications
    View official trial listing →
  • Completed NCT NCT04296149

    Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe

    Not yet reported European Institute of Oncology 5 participants Est. completion 2019-12-31 1 site Stand-alone
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Status unknown NCT NCT04353193

    Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial.

    Not yet reported Juan A. Arnaiz 36 participants Est. completion 2022-05 1 site Stand-alone
    Other conditions: Liver Cirrhosis Portal
    View official trial listing →
  • Completed NCT NCT04522297

    Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Syndrome

    Not yet reported National Hepatology & Tropical Medicine Research Institute 91 participants Est. completion 2020-01-23 1 site Stand-alone
    Other conditions: Hepato-Renal Syndrome
    View official trial listing →
  • Completed NCT NCT04552847

    Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors

    Not yet reported, Not yet reported Universitaire Ziekenhuizen KU Leuven 85 participants Est. completion 2022-02-08 1 site Stand-alone
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Status unknown NCT NCT04790708

    Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)

    Not yet reported University Hospital of Ferrara 250 participants Est. completion 2023-06-30 1 site
    Other conditions: Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy (PRRT)
    View official trial listing →
  • Completed NCT NCT04871204

    Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer

    Not yet reported Fredrik Klevebro 20 participants Est. completion 2024-02-21 1 site Stand-alone
    Other conditions: Esophageal Cancer, Gastric Cancer
    View official trial listing →
  • Withdrawn NCT NCT04915144

    177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

    Not yet reported British Columbia Cancer Agency Est. completion 2031-12-31 1 site
    Other conditions: Neuroendocrine Tumors, Carcinoid Tumor, Pulmonary Carcinoid Tumor, Gastroenteropancreatic Neuroendocrine Tumor, Vipoma, Insulinoma, Gastrinoma
    View official trial listing →
  • Active, not recruiting NCT NCT04919226

    Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

    Not yet reported ITM Solucin GmbH 259 participants Est. completion 2027-09 42 sites
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Status unknown NCT NCT04941911

    A Feasibility Study of Octreotide Infusion During Liver Transplant.

    Not yet reported University College, London 30 participants Est. completion 2024-01-31 2 sites
    Other conditions: Liver Transplantation, Renal Failure
    View official trial listing →
  • Active, not recruiting NCT NCT05050942

    A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

    Not yet reported Camurus AB 332 participants Est. completion 2028-11 86 sites Stand-alone
    Other conditions: Gastro-enteropancreatic Neuroendocrine Tumor
    View official trial listing →
  • Active, not recruiting NCT NCT05153772

    Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients

    Not yet reported Orano Med LLC 69 participants Est. completion 2030-12 4 sites Stand-alone
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Completed NCT NCT05171751

    Efficacy and Safety Evaluation of Octreotide in the Treatment of Congenital Hyperinsulinemia

    Beijing Children's Hospital 50 participants Est. completion 2021-12-18 1 site
    Other conditions: Congenital Hyperinsulinaemic Hypoglycaemia, Octreotide Adverse Reaction
    View official trial listing →
  • Status unknown NCT NCT05199038

    Comparison of 2 Days Versus 5 Days of Octreotide After Endoscopic Therapy in Preventing Early Esophageal Varices Rebleed : A Randomized Controlled Study

    Not yet reported Tanta University 184 participants Est. completion 2023-11 Stand-alone
    Other conditions: Esophageal Varices
    View official trial listing →
  • Active, not recruiting NCT NCT05281328

    A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

    Not yet reported, Not yet reported Camurus AB 71 participants Est. completion 2027-08 11 sites
    Other conditions: Polycystic Liver Disease
    View official trial listing →
  • Completed NCT NCT05340192

    Effect of Octreotide on Saliva

    Not yet reported Duke University 4 participants Est. completion 2020-02-26 1 site
    Other conditions: Healthy
    View official trial listing →
  • Status unknown NCT NCT05359146

    Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

    Not yet reported University Hospital, Basel, Switzerland 16 participants Est. completion 2025-12 1 site Stand-alone
    Other conditions: Neuroendocrine Neoplasia's (NENs), Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
    View official trial listing →
  • Completed NCT NCT05361668

    Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

    Not yet reported Crinetics Pharmaceuticals Inc. 36 participants Est. completion 2026-02-24 35 sites
    Other conditions: Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas
    View official trial listing →
  • Terminated NCT NCT05364944

    A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

    Not yet reported Debiopharm International SA 19 participants Est. completion 2024-12-03 14 sites Stand-alone
    Other conditions: Acromegaly, GEP-NET
    View official trial listing →
  • Active, not recruiting NCT NCT05459844

    A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

    Not yet reported Sinotau Pharmaceutical Group 196 participants Est. completion 2028-12 23 sites Stand-alone
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Completed NCT NCT05682209

    The Effect of Octreotide on Wound Drainage After Mastectomy

    Not yet reported Ikechukwu Bartholomew Ulasi 41 participants Est. completion 2021-12-02 1 site
    Other conditions: Seroma Following Procedure
    View official trial listing →
  • Completed NCT NCT05683444

    Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial

    Not yet reported Rigshospitalet, Denmark 16 participants Est. completion 2021-03-26 1 site
    Other conditions: Lymphatic Diseases, Chylothorax
    View official trial listing →
  • Completed NCT NCT05724134

    Pancreatic Clamp in NAFLD

    Not yet reported Columbia University 18 participants Est. completion 2025-09-24 1 site Stand-alone
    Other conditions: Insulin Resistance, Prediabetic State, Hyperinsulinemia, Non-Alcoholic Fatty Liver Disease, Obesity
    View official trial listing →
  • Completed NCT NCT05761431

    A Single-dose Study of Octreotide Injection in Healthy Adult Subjects

    Not yet reported CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 56 participants Est. completion 2023-06-28 1 site Stand-alone
    Other conditions: Acromegaly
    View official trial listing →
  • Status unknown NCT NCT05894486

    Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

    Not yet reported Peking University 40 participants Est. completion 2026-06-05 1 site Stand-alone
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Status unknown NCT NCT06062719

    Role of Octreotide in Non Variceal Bleeding

    Not yet reported, Not yet reported National Hepatology & Tropical Medicine Research Institute 56 participants Est. completion 2025-01 1 site Stand-alone
    Other conditions: Non-variceal Gastrointestinal Bleeding
    View official trial listing →
  • Completed NCT NCT06080204

    Real-world Study on Adjuvant Octreotide Therapy in pNETs

    Not yet reported Changhai Hospital 411 participants Est. completion 2020-04 Stand-alone
    Other conditions: Pancreatic Neuroendocrine Tumor G2
    View official trial listing →
  • Status unknown NCT NCT06085976

    Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.

    Not yet reported Clinica Universidad de Navarra, Universidad de Navarra 62 participants Est. completion 2025-11-30 1 site Stand-alone
    Other conditions: Hepatic Carcinoma, Hepatic Metastasis
    View official trial listing →
  • Withdrawn NCT NCT06126354

    Dexamethasone/Pancreatic Clamp P&F

    Not yet reported Columbia University Est. completion 2026-03-31 1 site Stand-alone
    Other conditions: Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT06193616

    Outcome of ADPKD With Octreotide LAR

    Mario Negri Institute for Pharmacological Research 70 participants Est. completion 2025-12 1 site
    Other conditions: Autosomal Dominant Polycystic Kidney
    View official trial listing →
  • Active, not recruiting NCT NCT06240039

    Direct Versus Indirect Effect of Amino Acids on Hepatokines

    Not yet reported University of Copenhagen 30 participants Est. completion 2028-09-01 1 site Stand-alone
    Other conditions: Non-Alcoholic Fatty Liver Disease, Obesity
    View official trial listing →
  • Completed NCT NCT06254235

    Bioequivalence Study of Two Octreotide Microsphere Formulations in Healthy Volunteers

    Not yet reported Qilu Pharmaceutical Co., Ltd. 240 participants Est. completion 2021-12-01 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Not yet recruiting NCT NCT06300216

    A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors

    Qilu Hospital of Shandong University 500 participants Est. completion 2028-05-26 1 site
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Not yet recruiting NCT NCT06558422

    Human Models of Selective Insulin Resistance: Pancreatic Clamp

    Not yet reported Columbia University 36 participants Est. completion 2029-02-28 1 site Stand-alone
    MASLD Other conditions: Insulin Resistance, Hyperinsulinemia, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
    View official trial listing →
  • Completed NCT NCT06753630

    Polydeoxyribonucleotide for Elbow Lateral Epicondylitis

    Not yet reported Chuncheon Sacred Heart Hospital 48 participants Est. completion 2016-11-30 1 site
    Other conditions: Lateral Epicondylitis, Extracorporeal Shockwave Therapy, Muscle Strengthening
    View official trial listing →
  • Terminated NCT NCT06865677

    Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

    Not yet reported National Cancer Institute (NCI) 2 participants Est. completion 2025-07-01 1 site Stand-alone
    Other conditions: Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma, Recurrent Epithelial Cervical Carcinoma
    View official trial listing →
  • Not yet recruiting NCT NCT06881888

    Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema

    Not yet reported University of Alabama at Birmingham 60 participants Est. completion 2027-12 1 site
    Other conditions: Diabetic Macular Edema
    View official trial listing →
  • Not yet recruiting NCT NCT06974344

    Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)

    Not yet reported King Faisal Specialist Hospital & Research Center 80 participants Est. completion 2030-09-01 1 site
    Other conditions: Small-for-Size Syndrome
    View official trial listing →
  • Not yet recruiting NCT NCT07102056

    18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms

    First Affiliated Hospital of Zhejiang University 152 participants Est. completion 2027-12-31
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Completed NCT NCT07460908

    Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome

    Not yet reported Lahore General Hospital 60 participants Est. completion 2025-10-30 1 site
    Other conditions: Hepatorenal Syndrome
    View official trial listing →
  • Not yet recruiting NCT NCT07479784

    Octreotide Microspheres for Preventing Pancreatic Fistula

    Not yet reported Shanghai Zhongshan Hospital 230 participants Est. completion 2028-12-31 Stand-alone
    Other conditions: Pancreatic Fistula
    View official trial listing →
  • Active, not recruiting NCT NCT07534371

    Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study

    West China Hospital 500 participants Est. completion 2026-07 1 site
    Other conditions: Neuroendocrine Tumors
    View official trial listing →
  • Not yet recruiting NCT NCT07623824

    A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly

    Not yet reported CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 154 participants Est. completion 2029-12-30
    Other conditions: Diagnosed With Acromegaly, Currently in the Active Stage of the Disease
    View official trial listing →
  • Completed NCT NCT07663318

    A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)

    Not yet reported Triastek (Shanghai) Limited 18 participants Est. completion 2026-07-24 1 site
    Other conditions: Acromegaly
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Octreotide, Octreotide Acetate

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.